Turvallisuus

Antroposofisten lääkevalmisteiden mahdolliset riskit,

sivuvaikutukset ja interaktiot

Spiess D, Winker M, Dolder Behna A, Gründemann C and Simões-Wüst AP (2022) Advanced in Vitro Safety Assessment of Herbal Medicines for the Treatment of Non-Psychotic Mental Disorders in Pregnancy. Front. Pharmacol. 13:882997. doi: 10.3389/fphar.2022.882997 Open access

Jong MC, van Wietmarschen H, Glockmann A, Baars EW, Hamre HJ.  Safety of Anthroposophic Medicinal Products: An analysis of adverse drug reactions from German pharmacovigilance databasesJDrugs - Real World Outcomes 2021.DOI: 10.1007/s40801-021-00262-7 

 

Thronicke A, Li Oei S, Merkle A, Matthes H, Schad, F. Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients. Medicines 2018, 5, 100; doi:10.3390/medicines5030100. Open access

Thronickea A, Li Oeia S, Merklea A Herbstreit C, Lemmens H-P, Grah C, Kröz M, Matthes H, Schad F. Integrative cancer care in a certified Cancer Centre of a German Anthroposophic hospital. Therapies in Medicine, Volume 40, October 2018, Pages 145-150 https://doi.org/10.1016/j.ctim.2018.03.012 Open access

Hamre HJ, Glockmann A, Heckenbach K and Matthes H. Use and Safety of Anthroposophic Medicinal Products: An Analysis of 44,662 Patients from the EvaMed Pharmacovigilance Network. 2017. Drugs - Real World Outcomes 4(4):1-15. DOI: 10.1007/s40801-017-0118-5 Open access 

Thronicke A, Steele ML, Grah C, Matthes B, Schad F. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. Complementary and Alternative Medicine 2017;17:534. 10 pp. DOI: 10.1186/s12906-017-2045-0

Schad F, Thronicke A, Merkle A, Matthes H, Steele ML (Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.  Phytomedicine 2017: 36: 54-58. DOI: 10.2016/j.phymed.2017.09.004

Huber R, Schlodder D, Effertz C, Rieger S, Tröger W (2017).Safety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancer. BMC Complementary and Alternative Medicine 2017;17:465. 8 pp. DOI: 10.1185/s12906-017-1971-1

Schink M, Dehus O. Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities. BMC Complemetary and Alternative Medicine 2017;17:521. 8 pp. DOI: 10.1186/s12096-017-2028-1

Steele ML, Axtner J, Happe A, Kröz, M, Matthes, H and Schad F. Use and Safety of Intratumoral Application of European Mistletoe (Viscum album L) Preparations in Oncology. Integr Cancer Ther March 2015 vol. 14 no. 2 140-148. DOI: 10.1177/1534735414563977 ict.sagepub.com. 

Steele ML, Axtner J, Happe A, Kröz, Matthes and Schad F. Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study. Evidence-Based Complementary and Alternative Medicine, 2014; Article ID 236310. Volume 2014,http://dx.doi.org/10.1155/2014/236310

Weissenstein U , Kunz M , Urech K and Baumgartner S. Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complementary and Alternative Medicine 2014, 14 :6 Open access: http://www.biomedcentral.com/1472-6882/14/6

Steele ML, Axtner J, Happe A, Kröz M, Matthes H and Schad F. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients. Evidence-Based Complementary and Alternative Medicine Volume 2014, Article ID 724258, 11 pages http://dx.doi.org/10.1155/2014/724258

Tröger, W.; Galun, D.; Reif, M.; Schumann, A.; Stanković, N.; Milićević, M. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Dtsch Ärztebl Int 2014; 111(29–30): 493–502. doi:10.3238/arztebl.2014.0493. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150026/;http://www.aerzteblatt.de/pdf.asp?id=161151

Tröger, W.; Ždrale, Z.; Tišma, N.; Matijašević, M. Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial. Evid Based Complement Alternat Med 2014: 430518. doi:10.1155/2014/430518. https://www.hindawi.com/journals/ecam/2014/430518/

Tröger, W.; Galun, D.; Reif, M.; Schumann, A.; Stanković, N.; Milićević, M. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomized clinical trial on overall survival. Eur. J. Cancer 2013; 49(18): 3788–3797. https://www.ncbi.nlm.nih.gov/pubmed/23890767;http://www.ejcancer.com/article/S0959-8049%2813%2900550-9/pdf

Mansky PJ, Wallerstedt DB, Sannes TS, Stagl J, Johnson LL, Blackman MR, Grem JL, Swain SM, Monahan BP:NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. Evidence-Based Complementary and Alternative Medicine 2013; 964592 http://www.hindawi.com/journals/ecam/2013/964592/

Schad F, Axtner J, Happe A, Breitkreuz T, Paxino C, Gutsch J, Matthes B, Debus M, Kröz M, Spahn G, Riess H, von Laue H and Matthes H.Network Oncology (NO) – a Clinical Cancer Register for Health Services Research and the Evaluation of Integrative Therapeutic Interventions in Anthroposophic Medicine. Forsch Komplementmed 2013;20:353–360 Published online: October 24, 2013 DOI: 10.1159/000356204 Accessible online at: www.karger.com/fok

Tröger, W.; Ždrale, Z.; Stanković, N.; Matijašević, M. 2012. Fiveyear follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with viscum album (L.) extract to chemotherapy alone. Breast Cancer (Auckl) 6: 173–180. doi:10.4137/BCBCR.S10558. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493140/

Jeschke E, Ostermann T, Tabali M, Kroz M, Bockelbrink A, Witt CM, Willich SN, Matthes H. Anthroposophic medicine in pediatric primary care: a prospective, multicenter observational study on prescribing patterns. H. Altern Ther Health Med 2011;17:18-28. 

Jeschke E, Ostermann T, Vollmar HC, Tabali M, Kröz M, Bockelbrink A, Witt CM, Willich SN, Matthes H.    Pharmacotherapy of elderly patients in everyday anthroposophic medical practice: a prospective, multicenter observational study. BMC 2010, 10:48. read more

Jeschke E, Ostermann T, Tabali M, Bockelbrink A, Witt C, Willich S, Matthes H. The treatment of children with anthroposophic medicine in daily primary care - Results of a network study. European Journal of Integrative Medicine 2009;1(4):203. read more

Jeschke E, Lueke C, Ostermann T, Tabali M, Huebner J, Matthes H. Prescribing practices in the treatment of upper respiratory tract infections in anthroposophic medicine. Forsch Komplementärmed 2007;14:207-15.

Jeschke E, Schad F, Pissarek J, Matthes B, Albrecht U, Matthes H. QuaDoSta - ein frei konfigurierbares System zur Unterstützung multizentrischer Datenerhebungen in medizinischer Versorgung und Forschung. GMS Med Inform Biom Epidemiol 2007;3(2):Doc 10.

Semiglasov VF, Stepula VV, Dudov A, Schnitker J, Mengs U.Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 2006, 26:1519-1530 http://ar.iiarjournals.org/content/26/2B/1519.full.pdf

Baars EW, Adriaansen-Tennekes R, Eikmans KJ. Safety of homeopathic injectables for subcutaneous administration: a documentation of the experience of prescribing practitioners. J Altern Complement Med 2005;11(4):609-616. 

Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 2004, 24:303-309 http://ar.iiarjournals.org/content/24/1/303.full.pdf